A Study to Evaluate the Effectiveness and Patient-Reported Outcome of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in China
NCT ID: NCT03236870
Last Updated: 2021-10-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
181 participants
OBSERVATIONAL
2017-09-08
2020-08-25
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Participants with moderate to severe plaque psoriasis in China
Participants with moderate to severe plaque psoriasis in China receiving adalimumab in daily clinical practice.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Moderate to severe plaque psoriasis patients eligible to use adalimumab according to the local label without any contraindication
* Patients have signed the authorization (or informed consent where applicable) to disclose and use personal health information after been prescribed with adalimumab.
Exclusion Criteria
* Patients in any psoriasis related clinical trial at the time of enrolment, at baseline or at any point during the study follow-up;
* Patients with active tuberculosis or other severe infections (e.g. sepsis and opportunistic infections) as well as moderate to severe cardiac insufficiency.
* Patients with difficulties for adequately reading, understanding and completing patient questionnaires.
18 Years
99 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AbbVie
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
AbbVie Inc.
Role: STUDY_DIRECTOR
AbbVie
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The First Affiliated Hospital /ID# 171398
Hefei, Anhui, China
Guangzhou 1st Muni People Hosp /ID# 208858
Guangzhou, Guangdong, China
Ruijin Hospital, Shanghai Jiaotong /ID# 169833
Shanghai, Shanghai Municipality, China
Traditional Chinese Medical Hospital of xinjiang uygur autonomous region /ID# 209183
Ürümqi, Xinjiang, China
The Second Affiliated Hospital /ID# 169842
Hangzhou, Zhejiang, China
Sir Run Run Shaw Hospital /ID# 169834
Jianggan Hangzhou, Zhejiang, China
Peking University 3rd Hospital /ID# 213443
Beijing, , China
Dermatology Hospital of southe /ID# 169830
Guangzhou, , China
2nd Aff. Hosp Harbin Med Univ /ID# 169827
Haerbin, , China
Shandong Provincial Hospital /ID# 169841
Jinan, , China
The Tenth People's Hospital of /ID# 169831
Shanghai, , China
The First Affiliated Hospital of Shantou University Medical College /ID# 209260
Shantou, , China
The 7th People's Hospital of Shenyang /ID# 169829
Shenyang, , China
Shenzhen Hospital of Southern /ID# 169828
Shenzhen, , China
Jing Tai Tianjin Hospital Co.,Ltd /ID# 208201
Tianjin, , China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
P15-986
Identifier Type: -
Identifier Source: org_study_id